We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Biolasers Light Up Circulating Tumor Cells in Bloodstream of Cancer Patients

By LabMedica International staff writers
Posted on 07 Jan 2025
Print article
Image: Researchers have developed new approach for identifying circulating tumor cells in patients with pancreatic and lung cancer (Photo courtesy of Jacob Dwyer/Michigan Medicine)
Image: Researchers have developed new approach for identifying circulating tumor cells in patients with pancreatic and lung cancer (Photo courtesy of Jacob Dwyer/Michigan Medicine)

As tumors grow, they release cells into the bloodstream, known as circulating tumor cells (CTCs). Although these cells are vastly outnumbered by millions of other blood cells, detecting them early can significantly enhance treatment outcomes. For example, pancreatic cancer is typically diagnosed too late for effective treatment, contributing to its poor prognosis. Similarly, lung cancer detection, especially for recurrence after treatment, is also challenging. Traditional methods for detecting CTCs involve labeling specific proteins on tumor cell surfaces with fluorescent dyes, making the cells easier to spot in blood samples. However, this method has drawbacks. Some CTCs may not express these proteins, causing them to be overlooked. Additionally, these methods miss valuable insights into the internal workings of the cancer cells, and often involve techniques that damage or kill the cells, preventing further analysis.

To find a way to detect CTCs while they remain alive, researchers from the University of Michigan (Ann Arbor, MI, USA) developed a new approach for identifying these cells in patients with pancreatic and lung cancer. The researchers turned to biolaser technology. While this approach still uses dyes to stain cancer cells, it does not kill them, and instead of focusing on proteins found on the cell surface, it targets something common to all cells—their nuclei. For their study, the researchers first passed blood samples from pancreatic cancer patients through a circular maze called Labyrinth, which pre-separates the CTCs, as they are slightly larger than other white blood cells. They then placed the tumor cells between two mirrors and directed an excitation laser at them, one cell at a time. When the excitation was strong enough, the cells emitted a laser, and these cells were referred to as "cell lasers." The laser emission from these cells is significantly stronger than what is observed with traditional fluorescent techniques.

Moreover, the images generated by laser emissions are distinct; while fluorescent images make the cells appear as glowing spheres, laser emissions reveal more complex shapes that provide insights into the organization of DNA inside the cancer cells. However, the differences in the laser emissions are subtle. To overcome this, the researchers used machine learning for enhanced accuracy. With the help of the Deep Cell-Laser Classifier model, they were able to identify pancreatic cancer cells with 99% accuracy. Impressively, the model, initially trained with pancreatic cancer cells, could also detect lung cancer cells without any additional training, as detailed in the study published in Biosensors and Bioelectronics. Moving forward, the researchers aim to develop a device capable of isolating cancer cells after detection. They also plan to use the unique light patterns produced by the cells to gain a deeper understanding of which tumors are more aggressive or resistant to treatment.

“With our system, if you want to collect circulating tumor cells, you have to remove the top mirror, which can cause the cell to move and then you lose track of it,” said Xudong (Sherman) Fan, professor of biomedical engineering. “We want to develop a system where cells move along one-by-one through the laser excitation spot and then go through a cell sorting device that helps us sort and collect cells for subsequent analysis.”

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.